Cabaletta Bio, Inc. Stock Price, News & Analysis

Cabaletta Bio (CABA) reported Q1 2022 financial results, revealing a net loss of $12.9 million, or $0.45 per share. Research and development expenses surged to $9.2 million, driven by ongoing clinical trials. The cash balance fell to $109.2 million from $122.2 million, expected to support operations until Q3 2023. Key advancements include progress in the DesCAARTes™ trial for mucosal pemphigus vulgaris and plans to initiate a first-in-human trial for MuSK-CAART in myasthenia gravis, following FDA Fast Track Designation.

Cabaletta Bio (Nasdaq: CABA) announced the presentation of data from its lead programs, DSG3-CAART and MuSK-CAART, at various scientific meetings in May 2022. The DSG3-CAART trial is currently in Phase 1, targeting mucosal pemphigus vulgaris. Presentations will showcase early cohort data and further characterization of DSG3-CAART cells. The MuSK-CAART program will include preclinical studies on myasthenia gravis. Key events are at the American Society of Gene & Cell Therapy and Society for Investigative Dermatology meetings.

Cabaletta Bio, a clinical-stage biotechnology company (Nasdaq: CABA), announced that Gwendolyn Binder, Ph.D., will present a pre-recorded session at the 21st Annual Needham Virtual Healthcare Conference.

This presentation will be available on-demand starting April 12, 2022, at 3:45 p.m. ET, and can be accessed via the company’s website, with replays available for 30 days. Cabaletta Bio focuses on developing targeted T cell therapies for autoimmune diseases, with a growing pipeline that includes treatments for conditions like pemphigus vulgaris and myasthenia gravis.

Cabaletta Bio, Inc. (CABA) reported its fourth quarter and full year 2021 financial results and provided a business update. The company ended 2021 with $122.2 million in cash, funding operations through Q3 2023. Significant advancements include the DesCAARTes™ trial, showing positive early results in cohorts, and the MuSK-CAART IND application cleared by the FDA with Fast Track Designation granted. Upcoming data presentations are scheduled for mid-2022, which are anticipated to provide insights into ongoing trials.

Cabaletta Bio has received Fast Track Designation from the FDA for its MuSK-CAART therapy, aimed at improving daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis (MG). The IND application was cleared, enabling a first-in-human clinical trial set to start in 2022 with approximately 20 patients. The trial will include dose escalation and cohort expansion. The therapy targets autoantibodies specifically, addressing a critical unmet need as current treatments have significant limitations.

Cabaletta Bio, a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that CEO Steven Nichtberger will join the Neuromuscular corporate panel at the Cowen Virtual 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET.

A live webcast will be accessible on the company's website, with replays available for 30 days. Cabaletta Bio's innovative CABA platform aims to develop therapies for conditions like pemphigus vulgaris and myasthenia gravis, positioning the company at the forefront of biotechnological advancements in autoimmune treatment.

Cabaletta Bio, a clinical-stage biotechnology company, has announced the promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer. Dr. Binder, previously Executive Vice President, has a strong background in engineered T cell therapy, while Dr. Das, formerly Executive Director of New Product Planning, has significant experience in business development. Both leaders will report to CEO Steven Nichtberger, emphasizing strategic contributions to enhance the company's mission to develop treatments for B cell-mediated autoimmune diseases.

Cabaletta Bio, a clinical-stage biotechnology company (Nasdaq: CABA), announced that CEO Steven Nichtberger, M.D. will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:00 a.m. ET. A live webcast will be available on their website, with a replay accessible for 90 days.

The company focuses on engineered T cell therapies for B cell-mediated autoimmune diseases. Their lead candidate, DSG3-CAART, is in the DesCAARTes™ Phase 1 clinical trial for pemphigus vulgaris and has received Fast Track Designation from the FDA.

Cabaletta Bio, a clinical-stage biotechnology company focused on engineered T cell therapies, announced that CEO Steven Nichtberger will present a pre-recorded company presentation at the H.C. Wainwright BioConnect Conference. This presentation will be available for on-demand viewing starting January 10, 2022, at 7:00 a.m. ET. The replay will be accessible on the company's website for 90 days. The company is developing therapies targeting B cell-mediated autoimmune diseases, including its lead candidate DSG3-CAART for mucosal pemphigus vulgaris, which has received Fast Track Designation from the FDA.